OBJECTIVE: The aim of this paper is to review the developments of farnesoid X receptor (FXR) biology, its ligands, and various functions, in particular we discuss the anti-inflammatory and anti-fibrotic role in chronic inflammatory diseases. INTRODUCTION: FXR is a ligand-dependent transcription factor belonging to the nuclear hormone receptor superfamily. The accrued data have shown that the FXR plays important roles not only in bile acid, lipid metabolism, and carbohydrate homeostasis, but also in inflammatory responses. The anti-inflammatory and anti-fibrotic effects of FXR on chronic inflammatory diseases are not well documented. METHODS: A literature survey was performed using PubMed database search to gather complete information regarding FXR and its role in inflammation. RESULTS AND DISCUSSION: FXR is highly expressed in liver, intestine, kidney and adrenals, but with lower expression in fat tissue, heart and recently it has been found to express in lungs too. Primary bile acids, cholic acid and chenodeoxycholic acid are the natural endogenous ligands for FXR. GW4064 and 6α-ethyl-chenodeoxycholic acid are the synthetic high-affinity agonists. An exhaustive literature survey revealed that FXR acts as a key metabolic regulator and potential drug target for many metabolic syndromes that include chronic inflammatory diseases.
OBJECTIVE: The aim of this paper is to review the developments of farnesoid X receptor (FXR) biology, its ligands, and various functions, in particular we discuss the anti-inflammatory and anti-fibrotic role in chronic inflammatory diseases. INTRODUCTION:FXR is a ligand-dependent transcription factor belonging to the nuclear hormone receptor superfamily. The accrued data have shown that the FXR plays important roles not only in bile acid, lipid metabolism, and carbohydrate homeostasis, but also in inflammatory responses. The anti-inflammatory and anti-fibrotic effects of FXR on chronic inflammatory diseases are not well documented. METHODS: A literature survey was performed using PubMed database search to gather complete information regarding FXR and its role in inflammation. RESULTS AND DISCUSSION: FXR is highly expressed in liver, intestine, kidney and adrenals, but with lower expression in fat tissue, heart and recently it has been found to express in lungs too. Primary bile acids, cholic acid and chenodeoxycholic acid are the natural endogenous ligands for FXR. GW4064 and 6α-ethyl-chenodeoxycholic acid are the synthetic high-affinity agonists. An exhaustive literature survey revealed that FXR acts as a key metabolic regulator and potential drug target for many metabolic syndromes that include chronic inflammatory diseases.
Authors: M A Serrano; R I R Macias; O Briz; M J Monte; A G Blazquez; C Williamson; R Kubitz; J J G Marin Journal: Placenta Date: 2006-05-19 Impact factor: 3.481
Authors: Michael Platten; Sawsan Youssef; Eun Mi Hur; Peggy P Ho; May H Han; Tobias V Lanz; Lori K Phillips; Matthew J Goldstein; Roopa Bhat; Cedric S Raine; Raymond A Sobel; Lawrence Steinman Journal: Proc Natl Acad Sci U S A Date: 2009-08-19 Impact factor: 11.205
Authors: Sunder Mudaliar; Robert R Henry; Arun J Sanyal; Linda Morrow; Hanns-Ulrich Marschall; Mark Kipnes; Luciano Adorini; Cathi I Sciacca; Paul Clopton; Erin Castelloe; Paul Dillon; Mark Pruzanski; David Shapiro Journal: Gastroenterology Date: 2013-05-30 Impact factor: 22.682
Authors: Reid M Huber; Kathleen Murphy; Bowman Miao; John R Link; Mark R Cunningham; Mark J Rupar; Paul L Gunyuzlu; Thomas F Haws; Altaf Kassam; Francoise Powell; Gregory F Hollis; Peter R Young; Ranjan Mukherjee; Timothy C Burn Journal: Gene Date: 2002-05-15 Impact factor: 3.688
Authors: Maneesh Bhargava; Kevin J Viken; Sanjoy Dey; Michael S Steinbach; Baolin Wu; Pratik D Jagtap; LeeAnn Higgins; Angela Panoskaltsis-Mortari; Daniel J Weisdorf; Vipin Kumar; Mukta Arora; Peter B Bitterman; David H Ingbar; Chris H Wendt Journal: Biol Blood Marrow Transplant Date: 2016-05-05 Impact factor: 5.742
Authors: Mary Francis; Grace Guo; Bo Kong; Elena V Abramova; Jessica A Cervelli; Andrew J Gow; Jeffrey D Laskin; Debra L Laskin Journal: Toxicol Sci Date: 2020-10-01 Impact factor: 4.849
Authors: S Banerjee; G Sindberg; F Wang; J Meng; U Sharma; L Zhang; P Dauer; C Chen; J Dalluge; T Johnson; S Roy Journal: Mucosal Immunol Date: 2016-02-24 Impact factor: 7.313
Authors: Karen R Jonscher; Alba Alfonso-Garcia; Jeffrey L Suhalim; David J Orlicky; Eric O Potma; Virginia L Ferguson; Mary L Bouxsein; Ted A Bateman; Louis S Stodieck; Moshe Levi; Jacob E Friedman; Daila S Gridley; Michael J Pecaut Journal: PLoS One Date: 2016-04-20 Impact factor: 3.240